Please assess the completion status of the following clinical trial:

Trial Title: Study of CMAB009 to Treat KRAS Wild Type Metastatic Colorectal Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* histologically confirmed metastatic colorectal adenocarcinoma~* KRAS wild-type tumors, EGFR-expressing or EGFR-nonexpressing by immunohistochemistry;~* has measurable lesion, at least 1cm in diametre by CT or MRI, at least 2cm diametre by physical examination or other iconography~* ECOG performance status 0 to 1~* Failure (disease progression/discontinuation due to toxicity) of fluoropyrimidine and oxaliplatin treatment,stop at least one month thereafter, irinotecan-naïve~Exclusion Criteria:~* Previous irinotecan or anti-EGFR therapies~* hematologic function: hemoglobin, less than 90g per liter; neutrophil count, less than 1500 per cubic millimeter; and platelet count, less than 100,000 per cubic millimeter~* liver function: bilirubin, more than 1.0 times the upper limit of normal; aspartate aminotransferase and alanine aminotransferase, more than 5.0 times and 2.5 times the upper limit of normal with hepatic metastasis or not~* Renal function: serum creatinine, more than 1.5 times the upper limit of normal~* Patients with symptomatic central nervous system metastases

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- CMAB009 plus Irinotecan (Type: EXPERIMENTAL): None
- Irinotecan-only and sequential-CMAB009 (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).